Bruker's Q1 Revenues Climb 14.9 Percent; Swings to Loss on Acquisition Charges | GenomeWeb
NEW YORK (GenomeWeb News) – Bruker today reported a 14.9 percent increase in first-quarter revenues, aided by a 9.9 percent currency benefit, but posted a loss due to $5.8 million in acquisition charges.
 
The Billerica, Mass.-based firm reported revenues of $238.4 million for the three-month period ended March 31, compared to revenues of $207.5 million in the first quarter of 2007. Bruker’s product revenues rose to $207 million from $181.6 million year over year, while service revenues increased to $30 million from $25.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.